190 related articles for article (PubMed ID: 24640678)
21. [The system stress-limiting action of mexidol in chronic cerebral ischemia].
Antipenko EA; Derugina AV; Gustov AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):28-31. PubMed ID: 27240044
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia].
Kataeva NG; Zamoshchina TA; Svetlik MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(11):59-63. PubMed ID: 33340299
[TBL] [Abstract][Full Text] [Related]
23. [The efficacy of mexidol for transient ischemic attacks in the vertebrobasilar system in elderly patients with chronic cerebral ischemia].
Abramenko YV
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(9. Vyp. 2):42-48. PubMed ID: 30499559
[TBL] [Abstract][Full Text] [Related]
24. [EVALUATED SERUM LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN MEN AND WOMEN WITH CHRONIC BRAIN ISCHEMIA].
Abramenko IuV; Sliusar' TA; Iakovlev NA
Adv Gerontol; 2015; 28(1):146-7. PubMed ID: 26390626
[TBL] [Abstract][Full Text] [Related]
25. [Cognitive impairment in children with organic asthenic disorder].
Chutko LS; Surushkina SY; Yakovenko EA; Anisimova TI; Cherednichenko DV; Didur MD; Chekalova SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9. Vyp. 2):92-99. PubMed ID: 37942979
[TBL] [Abstract][Full Text] [Related]
26. [THE INFLUENCE OF MEXIDOL AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE HEMISUCCINATE ON LIPOFUSCINE CONTENT IN RAT BRAIN UNDER LOCAL PERMANENT ISCHEMIA CONDITIONS].
Mirzoyan NR; Bagdasaryan NA; Alikhanyan CB; Meliksetyan VS; Bagdasaryan MG; Kukhtarova AM
Eksp Klin Farmakol; 2015; 78(8):3-6. PubMed ID: 26591573
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of the use of antioxidant preparation mexidol in comprehensive treatment of inflammatory diseases of parodontium].
Garazha NN; Garus IaN; Ivashova AV; Sakuro AA
Stomatologiia (Mosk); 2006; 85(6):19-21. PubMed ID: 17310943
[TBL] [Abstract][Full Text] [Related]
28. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
Bakalova RA; Hadzhimitova V; Ribarov S
Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
[TBL] [Abstract][Full Text] [Related]
29. [The effect of 3-hydroxypyridine derivatives on postischemic disorders in the autoregulatory reactions of the cerebral vessels].
Pogorelyĭ VE; Arl't AV; Gaevyĭ MD; Smirnov LD; Gatsura VV
Eksp Klin Farmakol; 1997; 60(4):22-4. PubMed ID: 9376750
[TBL] [Abstract][Full Text] [Related]
30. [The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis].
Zakharov VV; Vakhnina NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(1):82-88. PubMed ID: 38261288
[TBL] [Abstract][Full Text] [Related]
31. [Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency].
Belkin AA; Belkin VA; Vasilchenko IE; Pinchuk EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):108-117. PubMed ID: 38676685
[TBL] [Abstract][Full Text] [Related]
32. Antihypoxic and antinecrotic effect of mexidol in skin ischemia.
Galenko-Yaroshevskii VP; Bagmetova EN; Fil'chukova IA; Sidel'nikov AY; Popkov VA; Gorelashvili AS; Antelava NA; Sukoyan GV
Bull Exp Biol Med; 2005 Feb; 139(2):202-6. PubMed ID: 16027807
[TBL] [Abstract][Full Text] [Related]
33. [The use of mexidol in psychiatric practice].
Kosenko VG; Karagezian EA; Luneva LV; Smolenko LF
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):38-41. PubMed ID: 16841482
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications].
Pugacheva EL
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(5):84-89. PubMed ID: 35611905
[TBL] [Abstract][Full Text] [Related]
35. [Effect of mexidol on clinical and biochemical parameters of perinatal hypoxia in newborn children].
Levitina EV
Eksp Klin Farmakol; 2001; 64(5):34-6. PubMed ID: 11764497
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain].
Chukanova EI; Chukanova AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(9):39-45. PubMed ID: 31626217
[TBL] [Abstract][Full Text] [Related]
37. [Mexidol preparation influence upon lipids peroxide oxidation and oral fluid antioxidant system activity in patients with chronic generalized parodontitis and arterial hypertension].
Kazarina LN; Vdovina LV; Dubrovskaia EN
Stomatologiia (Mosk); 2010; 89(2):18-21. PubMed ID: 20517245
[TBL] [Abstract][Full Text] [Related]
38. [The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia].
Berezhnaya SV; Yakupov EZ; Zaharov YA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(5):23-27. PubMed ID: 27240176
[TBL] [Abstract][Full Text] [Related]
39. [Effect of mexidol on the homeostasis and lipid peroxidation in paracetamol poisoning].
Katikova OIu
Eksp Klin Farmakol; 2002; 65(6):53-6. PubMed ID: 12596535
[TBL] [Abstract][Full Text] [Related]
40. [Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia].
Belaia OL; Baĭder LM; Kuropteva ZV; Fomina IG
Klin Med (Mosk); 2005; 83(10):57-60. PubMed ID: 16320849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
